Customer complaints report low to no recovery of Campylobacter Jejuni ATCC 33291 on identified lot of medium.
Customer complaints report low to no recovery of Campylobacter Jejuni ATCC 33291 on identified lot of medium.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Remel, Inc or your healthcare provider for instructions. Notification method: Letter
Get instant alerts for Remel recalls
Be the first to know. Free instant alerts to your inbox.
Campy CVA Medium 100/PK, R01272. Reason: Customer complaints report low to no recovery of Campylobacter Jejuni ATCC 33291 on identified lot of medium.. Classification: Class II. Quantity: 97. Distribution: US Nationwide distribution in the states of AZ, CO, IL, NJ, OH, TN, WA.
Get instant alerts for recalls that affect you. Free forever.
Failed Dissolution Specifications: This recall has been initiated due to an Out of Specification finding in dissolution.
Labeling: Not Elsewhere Classified. The carton for Eptifibatide Injection 75 mg/100 mL states 75 mg/100 mL vial for weight-adjusted bolus dosing. The approved statement is 75 mg/100 mL vial for weight-adjusted infusion.
Lack of Assurance of Sterility: due to the presence of particulate matter in one unit from the lot, which lab tests have identified as wool fiber.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Software anomaly in the patient positioning system may result in positional discrepancy.
Software anomaly in the patient positioning system may result in positional discrepancy.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.